Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase

Journal of Medicinal Chemistry

Volumn 48, Issue 14, 2005, Pages 4596-4607

  Gaillard, Pascale ^a   Jeanclaude Etter, Isabelle ^a   Ardissone, Vittoria ^c   Arkinstall, Steve ^b   Cambet, Yves ^a   Camps, Montserrat ^a   Chabert, Christian ^a   Church, Dennis ^a   Cirillo, Rocco ^c   Gretener, Denise ^a   Halazy, Serge ^a   Nichols, Anthony ^a   Szyndralewiez, Cedric ^a   Vitte, Pierre Alain ^a   Gotteland, Jean Pierre ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b Serono Repro Biology Institute   (United States)

^c Serono International SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(BENZOTHIAZOL 2 YL)ACETONITRILE; 1,3 BENZOTHIAZOL 2 YL [2 [[2 (3 PYRIDINYL)ETHYL]AMINO] 4 PYRIMIDINYL]ACETONITRILEBIS(TRIFLUOROACETATE); AS 007149; AS 600292; AS 601245; BENZOTHIAZOLE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENTERITIS; HUMAN; HUMAN CELL; INFLAMMATION; LEUKEMIA CELL LINE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ACETONITRILES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; BENZOTHIAZOLES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JURKAT CELLS; MALE; MICE; MICE, INBRED C3H; MICE, INBRED DBA; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22244479745     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0310986     Document Type: Article

References (37)

1. Cobb, M. H.; Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem. 1995, 270, 14843-14846.
2. Minden, A.; Karin, M. Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta 1997, 1333, F85-F104.
3. Barr, R. K.; Bogoyevitch, M. A. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int. J. Biochem. Cell Biol. 2001, 33, 1047-1063.
4. Gupta, S.; Barrett, T.; Whitmarsh, A. J.; Cavanagh, J.; Sluss, H. K.; Derijard, B.; Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996, 15, 2760-2770.
5. Hibi, M.; Lin, A.; Smeal, T.; Minden, A.; Karin, M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 1993, 7, 2135-2148.
6. Whitmarsh, A. J.; Shore, P.; Sharrocks, A. D.; Davis, R. J. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995, 269, 403-407.
7. Chow, C. W.; Rincon, M.; Cavanagh, J.; Dickens, M.; Davis, R. J. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 1997, 278, 1638-1641.
8. Milne, D. M.; Campbell, L. E.; Campbell, D. G.; Meek, D. W. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J. Biol. Chem. 1995, 270, 5511-5518.
9. Gupta, S.; Barrett, T.; Whitmarsh, A. J.; Cavanagh, J.; Sluss, H. K.; Derijard, B.; Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996, 15, 2760-2770.
10. Gupta, S.; Barrett, T.; Whitmarsh, A. J.; Cavanagh, J.; Sluss, H. K.; Derijard, B.; Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996, 15, 2760-2770.
11. Mohit, A. A.; Martin, J. H.; Miller, C. A. p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron 1995, 14, 67-78.
12. Dong, C.; Yang, D. D.; Wysk, M.; Whitmarsh, A. J.; Davis, R. J.; Flavell, R. A. Defective T cell differentiation in the absence of Jnk1. Science 1998, 282, 2092-2095.
13. Yang, D. D.; Conze, D.; Whitmarsh, A. J.; Barrett, T.; Davis, R. J.; Rincon, M.; Flavell, R. A. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998, 9, 575-585.
14. Sabapathy, K.; Hu, Y.; Kallunki, T.; Schreiber, M.; David, J. P.; Jochum, W.; Wagner, E. F.; Karin, M. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 1999, 9, 116-125.
15. Tournier, C.; Hess, P.; Yang, D. D.; Xu, J.; Turner, T. K.; Nimnual, A.; Bar-Sagi, D.; Jones, S. N.; Flavell, R. A.; Davis, R. J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000, 288, 870-874.
16. Yang, D. D.; Kuan, C. Y.; Whitmarsh, A. J.; Rincon, M.; Zheng, T. S.; Davis, R. J.; Rakic, P.; Flavell, R. A. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997, 389, 865-870.
17. Lin, A. Activation of the JNK signaling pathway: Breaking the brake on apoptosis. Bioessays 2003, 25, 17-24.
18. Manning, A. M.; Davis, R. J. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discovery 2003, 2, 554-565.
19. Resnick, L.; Fennell, M. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discovery Today 2004, 9, 932-939.
20. Bennett, B. L.; Satoh, Y.; Lewis, A. J. JNK: a new therapeutic target for diabetes. Curr. Opin. Pharmacol. 2003, 3, 420-425.
21. Kennedy, N. J.; Davis, R. J. Role of JNK in tumor development. Cell Cycle 2003, 2, 199-201.
22. Bennett, B. L.; Sasaki, D. T.; Murray, B. W.; O'Leary, E. C.; Sakata, S. T.; Xu, W.; Leisten, J. C.; Motiwala, A.; Pierce, S.; Satoh, Y.; Bhagwat, S. S.; Manning, A. M.; Anderson, D. W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A 2001, 98, 13681-13686.
23. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371, 199-204.
24. Scapin, G.; Patel, S. B.; Lisnock, J.; Becker, J. W.; LoGrasso, P. V. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem. Biol. 2003, 10, 705-712.
25. Ruckle, T.; Biamonte, M.; Grippi-Vallotton, T.; Arkinstall, S.; Cambet, Y.; Camps, M.; Chabert, C.; Church, D. J.; Halazy, S.; Jiang, X.; Martinou, I.; Nichols, A.; Sauer, W.; Gotteland, J. P. Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase. J. Med. Chem. 2004, 47, 6921-6934.
26. Kundu, N. G.; Wright, J. A.; Perlman, K. L.; Hallett, W.; Heidelberger, C. Cyclopenta[f]isoquinoline derivatives designed to bind specifically to native deoxyribonucleic acid. 1. Synthesis of 3-ethoxy-8-methyl-7(5)H-cyclopenta[f] isoquinoline. J. Med. Chem. 1975, 18, 395-399.
27. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
28. Dumas, J. Protein kinase inhibitors: emerging pharmacophores 1997-2000. Expert Opin. Ther. Pat. 2001, 11, 405-429.
29. Jain, J.; Valge-Archer, V. E.; Rao, A. Analysis of the AP-1 sites in the IL-2 promoter. J. Immunol. 1992, 148, 1240-1250.
30. Paris, M.; Kokot, N.; Lee, L.; Nel, A. E. Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in jurkat T cells. Evidence for the importance of Ras in a pathway that is controlled by dual receptor stimulation. J. Biol. Chem. 1996, 271, 27366-27373.
31. Ventura, J. J.; Kennedy, N. J.; Lamb, J. A.; Flavell, R. A.; Davis, R. J. c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell. Biol. 2003, 23, 2871-2882.
32. Han, Z.; Boyle, D. L.; Aupperle, K. R.; Bennett, B.; Manning, A. M.; Firestein, G. S. Jun N-terminal kinase in rheumatoid arthritis. J. Pharmacol Exp. Ther. 1999, 291, 124-130.
33. Han, Z.; Boyle, D. L.; Chang, L.; Bennett, B.; Karin, M.; Yang, L.; Manning, A. M.; Firestein, G. S. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest 2001, 108, 73-81.
34. Han, Z.; Chang, L.; Yamanishi, Y.; Karin, M.; Firestein, G. S. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum. 2002, 46, 818-823.
35. Ferrandi, C.; Ballerio, R.; Gaillard, P.; Giachetti, C.; Carboni, S.; Vitte, P.-A.; Gotteland, J.-P.; Cirillo, R. Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br. J. Pharmacol. 2004, 142, 953-960.
36. Carboni, S.; Hiver, A.; Szyndralewiez, C.; Gaillard, P.; Gotteland, J. P.; Vitte, P. A. AS601245 (1,3-benzothiazol-2-yl(2-[[2-(3-pyridinyl)ethyl]amino] -4-pyrimidinyl)acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J. Pharmacol. Exp. Ther. 2004, 310, 25-32.
37. Potier, V.; Juillard, P.; Camps, M.; Gaillard, P.; Arkinstall, S.; Gotteland, J.-P.; Chvatchko, Y. Efficacy of a novel inhibitor in reducing lung fibrosis. Inflammation Res. 2003, 52 (Suppl. 2), 7.